カテゴリ： Allied Market Research, 世界, 医療/バイオ

遺伝性癌検査のグローバル市場（2021〜2031）：乳がん、胃がん、卵巣がん、前立腺がん、結腸直腸がん、その他

■ 英語タイトル：Hereditary Cancer Testing Market By Cancer Type (Breast Cancer, Gastric Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Other Cancers), By Test Type (Predictive Testing, Diagnostic Testing), By End User (Diagnostic Centers, Hospitals, Clinics): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB216）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB216
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：303
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[遺伝性癌検査のグローバル市場（2021〜2031）：乳がん、胃がん、卵巣がん、前立腺がん、結腸直腸がん、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に3,510.29百万ドルであった世界の遺伝性癌検査市場規模が、2031年までに10,087.49百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）11.6%で成長すると予測しています。本レポートは、遺伝性癌検査の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、がん種類別（乳がん、胃がん、卵巣がん、前立腺がん、その他）分析、検査別（予測用検査、診断用検査）分析、エンドユーザー別（診断センター、病院、クリニック）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Abbott Laboratories、Bio-Rad Laboratories, Inc.、CSL Ltd.、Danaher Corporation、EUROFINS SCIENTIFIC、F. HOFFMANN-LA ROCHE LTD、Illumina, Inc.、Myriad Genetics, Inc.、Qiagen NV、Thermo Fisher Scientific, Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の遺伝性癌検査市場規模：がん種類別
- 乳がんにおける市場規模
- 胃がんにおける市場規模
- 卵巣がんにおける市場規模
- 前立腺がんにおける市場規模
- その他における市場規模
・世界の遺伝性癌検査市場規模：検査別
- 予測用検査における市場規模
- 診断用検査における市場規模
・世界の遺伝性癌検査市場規模：エンドユーザー別
- 診断センターにおける市場規模
- 病院における市場規模
- クリニックにおける市場規模
・世界の遺伝性癌検査市場規模：地域別
- 北米の遺伝性癌検査市場規模
- ヨーロッパの遺伝性癌検査市場規模
- アジア太平洋の遺伝性癌検査市場規模
- 中南米・中東・アフリカの遺伝性癌検査市場規模
・企業状況
・企業情報

世界の遺伝性癌検査市場は、2021年に35億1,029万ドルと評価され、2022年から2031年までの年平均成長率は11.6%を記録し、2031年には100億8,749万ドルに達すると予測されています。

遺伝子検査は、生涯で癌を発症する可能性を推定するのに役立ちます。これは、突然変異と呼ばれる遺伝子、染色体、またはタンパク質における特定の変化を検索することによって行うことができます。遺伝子検査は、乳癌、卵巣癌、大腸癌、前立腺癌、膵臓癌、腎臓癌、胃癌など、いくつかの種類の癌で利用できます。自分の家族歴が癌のリスクになるかどうか心配な人は、遺伝カウンセラーに相談すべきです。個人的な病歴や家族歴の特徴、特に複合的な病歴は、異常に若い年齢で癌と診断されたとか、同じ人に複数の異なる種類の癌が発生したなど、遺伝性癌症候群を示唆する可能性があります。さらに、遺伝性癌検査は、その人に遺伝した癌の種類を確認することもできます。家族の中に遺伝性癌罹患症候群がすでに見つかっている人がいる場合、その変異型を受け継いでいる可能性のある家族は遺伝子検査を検討すべきです。リスクを知ることで、将来の癌を予防できる可能性があるからです。

遺伝性癌検査市場の成長の原動力となるのは、世界的な高齢者人口の増加と癌の罹患率の増加、そして医療に対する政府支出の急増です。さらに、遺伝性癌検査に関する認知度の向上と有利な償還政策が市場成長に寄与しています。しかし、熟練した専門家の不足と検査費用の高さが市場成長の妨げになると予想されます。逆に、未開拓の新興経済圏における高い成長の可能性は、市場に有利な機会をもたらすと期待されています。

遺伝性癌検査市場は、癌タイプ、検査タイプ、エンドユーザー、地域によって区分されます。癌タイプ別では、乳癌、胃癌、卵巣癌、前立腺癌、大腸癌、その他に分類されます。検査タイプ別では、予測検査と診断検査に分類されます。エンドユーザー別では、市場は診断センター、病院、クリニックに分類されます。さらに、病院セグメントはタイプ別に私立と公立に細分化されます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

本レポートに掲載されている主要企業には、Abbott Laboratories、Agilent Technologies, Inc.、Bio-Rad Laboratories, Inc.、Danaher Corporation、Eurofins Scientific SE、F. Hoffmann-La Roche AG、Illumina, Inc.、Myriad Genetics, Inc.、Qiagen N.V.、Thermo Fisher Scientific, Inc.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの遺伝性癌検査市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、遺伝性癌検査市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・遺伝性癌検査市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界の遺伝性癌検査市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
癌タイプ別
乳癌
胃癌
卵巣癌
前立腺癌
大腸癌
その他

検査タイプ別
予測検査
診断検査

エンドユーザー別
診断センター
病院
クリニック

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Abbott Laboratories
Bio-Rad Laboratories, Inc.
CSL Ltd.
Danaher Corporation
EUROFINS SCIENTIFIC
F. HOFFMANN-LA ROCHE LTD
Illumina, Inc.
Myriad Genetics, Inc.
Qiagen NV
Thermo Fisher Scientific, Inc.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Breast Cancer
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Gastric Cancer
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Ovarian Cancer
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Prostate Cancer
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Colorectal Cancer
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Other Cancers
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Predictive Testing
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Diagnostic Testing
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: HEREDITARY CANCER TESTING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Diagnostic Centers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Hospitals
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Hospitals Hereditary Cancer Testing Market by Type
6.3.4.1 Private Market size and forecast, by region
6.3.4.2 Public Market size and forecast, by region
6.4 Clinics
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: HEREDITARY CANCER TESTING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Cancer Type
7.2.3 North America Market size and forecast, by Test Type
7.2.4 North America Market size and forecast, by End User
7.2.4.1 North America Hospitals Hereditary Cancer Testing Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Cancer Type
7.2.5.1.2 Market size and forecast, by Test Type
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Cancer Type
7.2.5.2.2 Market size and forecast, by Test Type
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Cancer Type
7.2.5.3.2 Market size and forecast, by Test Type
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Cancer Type
7.3.3 Europe Market size and forecast, by Test Type
7.3.4 Europe Market size and forecast, by End User
7.3.4.1 Europe Hospitals Hereditary Cancer Testing Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Cancer Type
7.3.5.1.2 Market size and forecast, by Test Type
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Cancer Type
7.3.5.2.2 Market size and forecast, by Test Type
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Cancer Type
7.3.5.3.2 Market size and forecast, by Test Type
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Cancer Type
7.3.5.4.2 Market size and forecast, by Test Type
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Cancer Type
7.3.5.5.2 Market size and forecast, by Test Type
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Cancer Type
7.3.5.6.2 Market size and forecast, by Test Type
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Cancer Type
7.4.3 Asia-Pacific Market size and forecast, by Test Type
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.4.1 Asia-Pacific Hospitals Hereditary Cancer Testing Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Cancer Type
7.4.5.1.2 Market size and forecast, by Test Type
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Cancer Type
7.4.5.2.2 Market size and forecast, by Test Type
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Cancer Type
7.4.5.3.2 Market size and forecast, by Test Type
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Cancer Type
7.4.5.4.2 Market size and forecast, by Test Type
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Cancer Type
7.4.5.5.2 Market size and forecast, by Test Type
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Cancer Type
7.4.5.6.2 Market size and forecast, by Test Type
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Cancer Type
7.5.3 LAMEA Market size and forecast, by Test Type
7.5.4 LAMEA Market size and forecast, by End User
7.5.4.1 LAMEA Hospitals Hereditary Cancer Testing Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Cancer Type
7.5.5.1.2 Market size and forecast, by Test Type
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Cancer Type
7.5.5.2.2 Market size and forecast, by Test Type
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Cancer Type
7.5.5.3.2 Market size and forecast, by Test Type
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Cancer Type
7.5.5.4.2 Market size and forecast, by Test Type
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbott Laboratories
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bio-Rad Laboratories, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 CSL Ltd.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Danaher Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 EUROFINS SCIENTIFIC
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 F. HOFFMANN-LA ROCHE LTD
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Illumina, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Myriad Genetics, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Qiagen NV
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Thermo Fisher Scientific, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 2. HEREDITARY CANCER TESTING MARKET, FOR BREAST CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 3. HEREDITARY CANCER TESTING MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. HEREDITARY CANCER TESTING MARKET, FOR GASTRIC CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 5. HEREDITARY CANCER TESTING MARKET FOR GASTRIC CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. HEREDITARY CANCER TESTING MARKET, FOR OVARIAN CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 7. HEREDITARY CANCER TESTING MARKET FOR OVARIAN CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. HEREDITARY CANCER TESTING MARKET, FOR PROSTATE CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 9. HEREDITARY CANCER TESTING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. HEREDITARY CANCER TESTING MARKET, FOR COLORECTAL CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 11. HEREDITARY CANCER TESTING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. HEREDITARY CANCER TESTING MARKET, FOR OTHER CANCERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. HEREDITARY CANCER TESTING MARKET FOR OTHER CANCERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 15. HEREDITARY CANCER TESTING MARKET, FOR PREDICTIVE TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 16. HEREDITARY CANCER TESTING MARKET FOR PREDICTIVE TESTING, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. HEREDITARY CANCER TESTING MARKET, FOR DIAGNOSTIC TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 18. HEREDITARY CANCER TESTING MARKET FOR DIAGNOSTIC TESTING, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 20. HEREDITARY CANCER TESTING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 21. HEREDITARY CANCER TESTING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. HEREDITARY CANCER TESTING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. HEREDITARY CANCER TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. GLOBAL HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. HEREDITARY CANCER TESTING MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)
TABLE 26. HEREDITARY CANCER TESTING MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)
TABLE 27. HEREDITARY CANCER TESTING MARKET, FOR CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. HEREDITARY CANCER TESTING MARKET FOR CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. HEREDITARY CANCER TESTING MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 36. U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 37. U.S. HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 38. CANADA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 39. CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 40. CANADA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 41. MEXICO HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 43. MEXICO HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 44. EUROPE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. EUROPE HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 50. GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 51. GERMANY HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. FRANCE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 53. FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 55. UK HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 56. UK HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 57. UK HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 58. ITALY HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 59. ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 60. ITALY HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 61. SPAIN HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 62. SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 63. SPAIN HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 73. JAPAN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 74. JAPAN HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 75. CHINA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 76. CHINA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 77. CHINA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. INDIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 82. INDIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 83. INDIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 90. LAMEA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 91. LAMEA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. LAMEA HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. LAMEA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 96. BRAZIL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 97. BRAZIL HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 107.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 108.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 109.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 110.ABBOTT LABORATORIES: NET SALES,
TABLE 111.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 112.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 113.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 114.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 115.BIO-RAD LABORATORIES, INC.: NET SALES,
TABLE 116.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 117.CSL LTD.: COMPANY SNAPSHOT
TABLE 118.CSL LTD.: OPERATING SEGMENTS
TABLE 119.CSL LTD.: PRODUCT PORTFOLIO
TABLE 120.CSL LTD.: NET SALES,
TABLE 121.CSL LTD.: KEY STRATERGIES
TABLE 122.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 123.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 124.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 125.DANAHER CORPORATION: NET SALES,
TABLE 126.DANAHER CORPORATION: KEY STRATERGIES
TABLE 127.EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 128.EUROFINS SCIENTIFIC: OPERATING SEGMENTS
TABLE 129.EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 130.EUROFINS SCIENTIFIC: NET SALES,
TABLE 131.EUROFINS SCIENTIFIC: KEY STRATERGIES
TABLE 132.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 133.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 134.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 135.F. HOFFMANN-LA ROCHE LTD: NET SALES,
TABLE 136.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 137.ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 138.ILLUMINA, INC.: OPERATING SEGMENTS
TABLE 139.ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 140.ILLUMINA, INC.: NET SALES,
TABLE 141.ILLUMINA, INC.: KEY STRATERGIES
TABLE 142.MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
TABLE 143.MYRIAD GENETICS, INC.: OPERATING SEGMENTS
TABLE 144.MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
TABLE 145.MYRIAD GENETICS, INC.: NET SALES,
TABLE 146.MYRIAD GENETICS, INC.: KEY STRATERGIES
TABLE 147.QIAGEN NV: COMPANY SNAPSHOT
TABLE 148.QIAGEN NV: OPERATING SEGMENTS
TABLE 149.QIAGEN NV: PRODUCT PORTFOLIO
TABLE 150.QIAGEN NV: NET SALES,
TABLE 151.QIAGEN NV: KEY STRATERGIES
TABLE 152.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 153.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 154.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 155.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 156.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 泌尿生殖器治療薬のグローバル市場2023-2030：前立腺がん、卵巣がん、膀胱がん、子宮頸がん、尿路結石、性病
  • 尿路感染症検査のグローバル市場（2021～2031）：尿道炎、膀胱炎、腎盂腎炎
  • C型肝炎検査のグローバル市場（2021〜2031）：イムノアッセイ、PCR、その他技術
  • HPV検査＆パップテストのグローバル市場（2021〜2031）：HPV検査、パップテスト、同時検査
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB216 )"遺伝性癌検査のグローバル市場（2021〜2031）：乳がん、胃がん、卵巣がん、前立腺がん、結腸直腸がん、その他" (英文：Hereditary Cancer Testing Market By Cancer Type (Breast Cancer, Gastric Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Other Cancers), By Test Type (Predictive Testing, Diagnostic Testing), By End User (Diagnostic Centers, Hospitals, Clinics): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。